

Heme Malignancy Disease-Oriented Team

Clinical Research Treatment Trial Flowchart

Clinical Research Manager:
Blake Johnson

Clinical Research Coordinators:
Emiri Matsuda
Stephanie Osorio
Judit Castellanos
Kelsey McAbee
Regan Dagenhart
Harleen Mehrok
Alireza Saatchi

Data Coordinators:
Alice Ting
Heather Franson

Newly diagnosed

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

Front Line

ETCTN 10538

Venetoclax+ASTX727 (All oral therapy) for CMML, MDS/MPN with excess blasts

Accrual: 0/5

Coord: Kelsey McAbee
Mechanism: BCL-2 selective inhibitor

Observational Study

UCI 23-32

Dissecting the mechanism of Interferon Alpha (IFN) response in MPN

Coord: N/A
Mechanism: observational study

Supportive Care

UCI 20-50

N-Acetylcysteine in MPN to Improve Disease Markers & Symptoms

Accrual 10/27

Coord: Kelsey McAbee
Mechanism: Mucolytic agent (cysteine and GSH precursor)

Relapsed/Refractory

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

2nd Line+

UCI 20-51

IO-202 in R/R AML patients w/
monocytic differentiation and in
R/R CMML patients

Accrual: 4/5

Coord: Stephanie Osorio
Mechanism: LILRB4 antibody

Relapsed/Refractory

■ Open to Accrual

■ Low Accruing

■ Pending Activation/Suspended

High-Risk

UCI 22-151LYT-200 in patients w/ R/R AML
or high-risk MDS

Accrual: 3/5

Coord: Stephanie Osorio
Mechanism: Galectin-9
monoclonal antibody

Low-Risk

UCI 21-239IRAK 1/4 inhibitor, R289, in patients
w/ refractory or resistant lower-risk
MDS

Accrual: 0/5

Coord: Stephanie Osorio
Mechanism: IRAK1/4 inhibitor

Molecularly-Driven

IDH

UCI 21-144HMPL-306 in advanced
hematological malignances w/
IDH mutations

Accrual: 0/5

Coord: Stephanie Osorio
Mechanism: IDH1/2 inhibitor

HSCT

UCI 23-113Oral GLB-001 in patients w/ R/R
AML or high-risk MDS

Accrual: 0/7

Coord: Stephanie Osorio
Mechanism: Selective molecular
glue degrader

Newly diagnosed

■ Open to Accrual
 ■ Low Accruing
 ■ Pending Activation/Suspended

Intensive

UCI 18-105

The combination of CPX-351 and Glasdegib in previously undertreated patients w/ AML w/ MDS related changes or therapy related AML

Accrual: 25/30

Coord: Kelsey McAbee
 Mechanism: Hedgehog pathway inhibitor+liposomal formulation of cytoxic chemotherapy Danorubicin & Cytarabine

Non-Intensive

FLT3 mutation

UCI 21-216

Giltertinib+Venetoclax+Azacitidine in patients w/ FLT3 mutant AML not eligible for intensive induction chemotherapy

Accrual: 1/5

Coord: Stephanie Osorio
 Mechanism: FLT3 inhibitor

KMT2A-r/NPM1-m

UCI 23-44

Venetoclax/Azacitidine v.s Venetoclax+ KO-530 v.s cytarabine/daunorubicin (7+3)+ KO-539 in AML

Accrual: 1/6

Coord: Stephanie Osorio
 Mechanism: menin inhibitor

CD123+

UCI 19-138

IMGN632 as monotherapy or combination w/ Venetoclax and/or Azacitidine for patients w/ CD123-positive AML

Accrual: 2/5

Coord: Stephanie Osorio
 Mechanism: CD123 antibody

Relapsed/Refractory

■ Open to Accrual
 ■ Low Accruing
 ■ Pending Activation/Suspended

2nd Line+

UCI 22-151

LYT-200 in patients w/ R/R AML or high-risk MDS

Accrual: 3/5

Coord: Stephanie Osorio
Mechanism: Galectin-9 monoclonal antibody

UCI 22-81

HM43239 in patients w/ R/R AML

Accrual: 0/6

Coord: Stephanie Osorio
Mechanism: FLT3 inhibitor

UCI 23-154

Ziftomenib combinations for the KMT2A-rearranged/NPM1 mutant R/R AML

Accrual: 0/5

Coord: Stephanie Osorio
Mechanism: menin inhibitor

UCI 23-113

Oral GLB-001 in patients w/ R/R AML or high-risk MDS

Accrual: 0/7

Coord: Stephanie Osorio
Mechanism: Selective molecular glue degrader

Molecularly-Driven

IDH

UCI 21-144

HMPL-306 in advanced hematological malignances w/ IDH mutations

Accrual: 0/5

Coord: Stephanie Osorio
Mechanism: IDH1/2 inhibitor

Menin

UCI 22-24

BMF-219 in patients w/ AL, DLBCL, MM, CLL/SLL

Accrual: 1/5

Coord: Judit Castellanos
Mechanism: menin inhibitor

Relapsed/Refractory

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

Maintenance

High-Risk, HSCT

Molecularly-Driven

KMT2A-r/NPM1-m

UCI 23-44

Venetoclax/Azacitidine v.s
Venetoclax+ KO-530 v.s
cytarabine/daunorubicin (7+3)+
KO-539 in AML

Accrual: 1/6

Coord: Stephanie Osorio
Mechanism: menin inhibitor

Salvage Therapy

UCI 19-93

DFP-10917 vs. non-intensive
reinduction or intensive
reinduction for AML patients
in 2nd or 3rd salvage

Accrual: 11/12

Coord: Stephanie Osorio
Mechanism: Nucleoside
analog

Newly diagnosed

■ Open to Accrual
 ■ Low Accruing
 ■ Pending Activation/Suspended

Ph+ only

EA9181

Steroids +TKI w/ chemotherapy or Blinatumomab for BCR-ABL positive adult patients

Accrual 12/35

Coord: Harleen Mehrok
 Mechanism: BiTE binding to CD19 (on B-cell) and CD3 (on T-cells) and PD-1 inhibitor

Ph- only

UCI 21-98

Blinatumomab altering w/ low-intensity chemotherapy vs. SOC for older adult patients

Accrual: 5/6

Coord: Judit Castellanos
 Mechanism: BiTE binding to CD19 (on B-cell) and CD3 (on T-cells) and PD-1 inhibitor

Ph+ or Ph-

A041501

Addition of Inotuzumab Ozogamicin to frontline therapy in young adults (18-39y/o)

Accrual: 10/15

Coord: Judit Castellanos
 Mechanism: conjugated anti-CD22 monoclonal antibody

UCI 22-125

Calaspargase pegol for tx of adults 22-65y/o w/ newly diagnosed Ph- ALL

Accrual: 0/5

Coord: Judit Castellanos
 Mechanism: PEGylated conjugate L-asparaginase

UCI 21-14

Levocarnitine for Asparaginase hepatotoxicity in ALL patients

Accrual: 0/5 (opened 11/3/23)

Coord: Judit Castellanos
 Mechanism: Oxidative stress reducer & inflammatory modulator

Relapsed/Refractory

CR w/ MRD+

UCI 20-34

Outpatient Blinatumomab in adult patients w/ MRD of pre B-ALL in CR

Accrual: 2/5

Coord: Judit Castellanos
Mechanism: BiTE binding to CD19 (on B-cell) and CD3 (on T-cells) and PD-1 inhibitor

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

Molecularly-Driven

CD22+

A041703

Inotuzumab Ozogamicin followed by Blinatumomab for ph- CD22-positive newly diagnosed or R/R ALL patients

Accrual: 2/5

Coord: Judit Castellanos
Mechanism: antibody-drug conjugate combining a monoclonal antibody targeting CD22 on B-lymphoblast with the cytotoxic agents

Menin

UCI 22-24

BMF-219 in patients w/ AL, DLBCL, MM, CLL/SLL

Accrual: 1/5

Coord: Judit Castellanos
Mechanism: menin inhibitor

Newly diagnosed

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

High-Risk

S1925

Venetoclax+Obnutumab early intervention vs. delayed therapy in asymptomatic high-risk CLL/SLL

Accrual: 1/10

Coord: Stephanie Osorio
Mechanism: BCL2 inhibitor +anti-CD20 monoclonal antibody

Front Line

UCI 23-156

Sonrotoclax (BGB-11417) + Zanubrutinib (BGB-3111) v.s. Venetoclax +Obinutuzumab

Accrual: 0/7

Coord: Ali Saatchi
Mechanism: BTK + BCL2 inhibition

Relapsed/Refractory

■ Open to Accrual

■ Low Accruing

■ Pending Activation/Suspended

Molecularly-Driven

Menin

UCI 22-24BMF-219 in patients w/ AL,
DLBCL, MM, CLL/SLL

Accrual: 1/5

Coord: Judit Castellanos
Mechanism: menin inhibitor

Cell Therapy

UCI 21-19MB-106 in patients w/ R/R CD20+
B-cell NHL or CLL

Accrual: 1/5

Coord: Regan Dagenhart
Mechanism: anti-CD20 chimeric
antigen receptor2nd Line+UCI 21-209LOXO-305 + Venetoclax and
Rituximab vs. Venetoclax and
Rituximab in previously treated
CLL/SLL

Accrual: 2/3

Coord: Stephanie Osorio
Mechanism: BTK inhibitor + BCL2
inhibitor + CD20 marker3rd Line+UCI 22-134Oral AS-1763 in patients w/
previously treated CLL/SLL or NHL

Accrual: 1/5

Coord: Emiri Matsuda
Mechanism: BTK inhibitor for both
wild-typ and C481S-mutant typeUCI 20-198NX-2127, Bruton's tyrosine
kinase degrader, in adults w/
R/R B-cell malignancies

Accrual: 1/3

Coord: Stephanie Osorio
Mechanism: BTK degrader +
iMiD

Relapsed/Refractory

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

2nd Line+

UCI 23-167

Phase I- TERN-701 in patients
w/CML

Accrual: 1/5

Coord: Kelsey McAbee

Mechanism: STAMP inhibitor

Newly Diagnosed

■ Open to Accrual
 ■ Low Accruing
 ■ Pending Activation/Suspended

ASCT- Maintenance

UCI 23-70

The efficacy and safety of
 Idecabtagene Vicleucef +
 Lenalidomide v.s. Lenalidomide as
 single maintenance therapy
 * Induction therapy + ASCT required

Accrual: 0/6

Coord: Harleen Mehrok
 Mechanism: BCMA-directed
 autologous T-cell immunotherapy

Front Line- Bispecific

UCI 23-158

Phase I/II Study of Linvoseltamab
 (Anti-BCMA X Anti-CD3 Bispecific
 Antibody) in Previously Untreated
 Patients with Symptomatic Multiple
 Myeloma
 Accrual: 0/6

Coord: Emiri Matsuda
 Mechanism: Bispecific antibody
 (BCMA x CD3)

Relapsed/Refractory

■ Open to Accrual

■ Low Accruing

■ Pending Activation/Suspended

Maintenance

S1803

Daratumumab/rHuPH20 +
lenalidomide vs. lenalidomide as post
auto ASCT maintenance therapy

Accrual: 10/15

Coord: Judit Castellanos
Mechanism: anti-CD38 monoclonal
antibody

Molecularly-Driven

Menin

UCI 22-24

BMF-219 in patients w/ AL,
DLBCL, MM, CLL/SLL

Accrual: 1/5

Coord: Judit Castellanos
Mechanism: menin inhibitor

2nd Line+UCI 22-190

Teclistamab monotherapy vs.
PVD or KD in patients received
1-3 prior lines of therapy

Accrual: 2/3

Coord: Emiri Matsuda
Mechanism: CD3 x BCMA BiTE

Newly diagnosed

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

Front Line

UCI 23-17

Odronextamab (REGN1979) vs.
investigator's choice in patient w/ FL

Coord: Regan Dagenhart

Mechanism: Anti-CD20 x Anti-CD3
bispecific antibody

Relapsed/Refractory

■ Open to Accrual

■ Low Accruing

■ Pending Activation/Suspended

Cell Therapy

UCI 21-19

MB-106 in patients w/ R/R CD20+ B-cell NHL or CLL

Accrual: 1/5

Coord: Regan Dagenhart

Mechanism: anti-CD20 **chimeric antigen receptor**

UCI 22-01

Axicabtagene Ciloleucel vs. SOC in patients w/ R/R FL

Accrual: 0/5

Coord: Regan Dagenhart

Mechanism: anti-CD19 **CAR T-cell**

3rd Line+UCI 22-134

Oral AS-1763 in patients w/ previously treated CLL/SLL or NHL

Accrual: 1/5 (opened 11/21/23)

Coord: Emiri Matsuda

Mechanism: BTK inhibitor for both wild-typ and C481S-mutant type

UCI 20-198

NX-2127, Bruton's tyrosine kinase degrader, in adults w/ R/R B-cell malignancies

Accrual: 1/3

Coord: Regan Dagenhart

Mechanism: BTK degrader + iMiD

Consolidation

S2114

Consolidation therapy following CD19 CAR T-cell tx

Accrual: 0/6

Coord: Emiri Matsuda

Mechanism: bite/mab

Molecularly-Driven

Relapsed/Refractory

■ Open to Accrual

■ Low Accruing

■ Pending Activation/Suspended

Cell Therapy

UCI 21-19

MB-106 in patients w/ R/R
CD20+ B-cell NHL or CLL

Accrual: 1/5

Coord: Regan Dagenhart

Mechanism: anti-CD20 **chimeric
antigen receptor**

3rd Line+UCI 22-134

Oral AS-1763 in patients w/
previously treated CLL/SLL or NHL

Accrual: 1/5

Coord: Emiri Matsuda

Mechanism: BTK inhibitor for both
wild-typ and C481S-mutant type

Molecularly-Driven

UCI 21-04

Nanatinostat + Valganciclovir in
patients w/ EBV+ R/R lymphomas

Accrual: 0/2

Coord: Regan Dagenhart

Mechanism: selective HDAC class I
inhibitor

UCI 20-198

NX-2127, Bruton's tyrosine
kinase degrader, in adults w/
R/R B-cell malignancies

Accrual: 1/3

Coord: Regan Dagenhart

Mechanism: BTK degrader +
iMiD

Relapsed/Refractory

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

Cell Therapy

UCI 21-19

MB-106 in patients w/ R/R
CD20+ B-cell NHL or CLL

Accrual: 1/5

Coord: Regan Dagenhart
Mechanism: anti-CD20 chimeric
antigen receptor

3rd Line+

UCI 22-134

Oral AS-1763 in patients w/
previously treated CLL/SLL or NHL

Accrual: 1/5

Coord: Emiri Matsuda
Mechanism: BTK inhibitor for both
wild-typ and C481S-mutant type

Molecularly-Driven

Newly diagnosed

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

75 y/o Older

S1918

R-miniCHOP w/ or w/o oral
Azacitidine in patients 75 y/o or
older

Accrual: 3/10

Coord: Regan Dagenhart
Mechanism: Oral
hypomethylating agent

Relapsed/Refractory

■ Open to Accrual
 ■ Low Accruing
 ■ Pending Activation/Suspended

Primary Relapsed/Refractory

UCI 21-225

Glofitamab+ R-ICE in patients w/
R/R transplant eligible DLBCL

Accrual: 9/10

Coord: Regan Dagenhart
Mechanism: T-cell bispecific
antibody targeting CD20 (B-cell) and
CD3ε chain T-cell)

Cell Therapy- CRS mgmt

UCI 23-193

CTO1681 for the Prevention and
Treatment of CRS in Patients with
DLBCL receiving Chimeric Antigen
Receptor T-Cell Therapy

Accrual: 0/5

Coord: Judit Castellanos
Mechanism: PGE2 & PGI2 agonist

Secondary Relapsed/Refractory

UCI 21-19

MB-106 in patients w/ R/R
CD20+ B-cell NHL or CLL

Accrual: 1/5

Coord: Regan Dagenhart
Mechanism: anti-CD20
**CHIMERIC ANTIGEN
RECEPTOR**

UCI 20-126

CB-010, CRISPR-edited
allogeneic anti-CD19 CAR-T
cell therapy

Accrual: 5/7

Coord: Emiri Matsuda
Mechanism: anti-CD19
**CHIMERIC ANTIGEN
RECEPTOR**

Relapsed/Refractory

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

Tertiary Relapsed/Refractory

UCI 22-24

BMF-219 in patients w/ AL, DLBCL, MM, CLL/SLL

Accrual: 1/5

Coord: Stephanie Osorio
Mechanism: menin inhibitor

S2114

Consolidation therapy following CD19 CAR T-cell tx

Accrual: 0/6

Coord: Emiri Matsuda
Mechanism: bite/mab

UCI 20-198

NX-2127, Bruton's tyrosine kinase degrader, in adults w/ R/R B-cell malignancies

Accrual: 1/3

Coord: Regan Dagenhart
Mechanism: BTK degrader + iMiD

Molecularly-Driven

Relapsed/Refractory

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

Molecularly-Driven

Basket study

Newly diagnosed

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

COG ANHL1931

Nivolumab + chemo-immunotherapy

Accrual: 2/5

Coord: Regan Dagenhart
Mechanism: PD1 inhibitor

Relapsed/Refractory

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

Consolidation

S2114

Consolidation therapy following
CD19 CAR T-cell tx

Accrual: 0/6

Coord: Emiri Matsuda
Mechanism: bite/mab

Molecularly-Driven

Relapsed/Refractory

■ Open to Accrual

■ Low Accruing

■ Pending Activation/Suspended

Cell Therapy

UCI 21-19

MB-106 in patients w/ R/R CD20+ B-cell NHL or CLL

Accrual: 1/5

Coord: Regan Dagenhart
Mechanism: anti-CD20 chimeric antigen receptor

3rd line+

UCI 22-134

Oral AS-1763 in patients w/ previously treated CLL/SLL or NHL

Accrual: 1/5 (opened 11/21/23)

Coord: Emiri Matsuda
Mechanism: BTK inhibitor for both wild-typ and C481S-mutant type

Molecularly-Driven

UCI 23-114

Safety and Efficacy of IMPT-314, a CD19/20 Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy in B-cell NHL

Accrual: 0/7

Coord: Kelsey McAbee
Mechanism: CD19/20 bispecific CAR

UCI 20-198

NX-2127, Bruton's tyrosine kinase degrader, in adults w/ R/R B-cell malignancies

Accrual: 1/3

Coord: Regan Dagenhart
Mechanism: BTK degrader + iMiD

Relapsed/Refractory

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

Molecularly-Driven

Relapsed/Refractory

■ Open to Accrual

■ Low Accruing

■ Pending Activation/Suspended

2nd Line+

UCI 21-224

KT-333 in R/R lymphomas,
LGLL and solid tumors

Accrual: 0/5

Coord: Regan Dagenhart
Mechanism: STAT3 degrader

3rd Line+

UCI 21-99

ONO-4685 given as
monotherapy

Accrual: 1/10

Coord: Regan Dagenhart
Mechanism: CD3-bispecific
antibody targeting PD-1

Molecularly-Driven

UCI 21-144

HMPL-306 in advanced
hematological malignances w/
IDH mutations

Accrual: 0/5

Coord: Stephanie Osorio
Mechanism: IDH1/2 inhibitor

Supportive Care

UCI 14-03
Role of Inflammation in the Pathogenesis of Myeloproliferative Neoplasm

UCI 15-65
Effect of candidate blood cancer therapies on normal human lymphocytes

Long-Term FU

UCI 21-184
Long-term safety of CAR-T inpatient w/ heme malignancies
Accrual: 2/5
Coord: Emiri Matsuda

UCI 21-90
Risk-ADAPTEd conditionin regimen for AHST
Accrual: 4/48
Coord: Emiri Matsuda

Polycythemia vera

UCI 21-204

ISIS702843 in patients w/ PD-PC

Mechanism: Antisense oligonucleotide specific for human transmembrane protease serine 6

Accrual: 1/5
Coord: Kelsey McAbee

HSCT Transplant

UCI 22-188

Prospective evaluation of CMV-TCIP directed Letemovir ppx after AHCT

Coord: Emiri Matsuda
Mechanism: anti-CMV